本文约2000字,阅读时长约5分钟12月29日,国家药监局药品通知件信息显示,合肥天汇生物的重组人胰岛素肠溶胶囊 ORMD-0801 注册申请终止,意味着这款“首个申报上市的口服胰岛素”暂时无缘中国市场。企业称属于主动撤回、配合整体战略调整,但在糖尿病患者数接近 1.5 亿、中国已成为全球糖尿病第一大国的背景下,一款有望让患者减少注射、改为吞一粒胶囊的创新药受挫,折射出胰岛素治疗从“每天打一针”到...
Source Link本文约2000字,阅读时长约5分钟12月29日,国家药监局药品通知件信息显示,合肥天汇生物的重组人胰岛素肠溶胶囊 ORMD-0801 注册申请终止,意味着这款“首个申报上市的口服胰岛素”暂时无缘中国市场。企业称属于主动撤回、配合整体战略调整,但在糖尿病患者数接近 1.5 亿、中国已成为全球糖尿病第一大国的背景下,一款有望让患者减少注射、改为吞一粒胶囊的创新药受挫,折射出胰岛素治疗从“每天打一针”到...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.